Point72 Asia Singapore Pte. Ltd. Purchases New Position in Vor Biopharma Inc. (NYSE:VOR)

Point72 Asia Singapore Pte. Ltd. acquired a new stake in Vor Biopharma Inc. (NYSE:VOR) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 63,262 shares of the company’s stock, valued at approximately $63,000. Point72 Asia Singapore Pte. Ltd. owned approximately 0.09% of Vor Biopharma at the end of the most recent reporting period.

Other institutional investors and hedge funds have also made changes to their positions in the company. Acadian Asset Management LLC purchased a new stake in shares of Vor Biopharma in the first quarter valued at approximately $126,000. Vanguard Group Inc. increased its position in shares of Vor Biopharma by 4.0% in the first quarter. Vanguard Group Inc. now owns 1,812,899 shares of the company’s stock valued at $4,297,000 after buying an additional 69,436 shares in the last quarter. Renaissance Technologies LLC increased its position in shares of Vor Biopharma by 48.0% in the second quarter. Renaissance Technologies LLC now owns 495,300 shares of the company’s stock valued at $495,000 after buying an additional 160,642 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new stake in shares of Vor Biopharma in the second quarter valued at approximately $53,000. Finally, Hsbc Holdings PLC increased its position in shares of Vor Biopharma by 177.0% in the second quarter. Hsbc Holdings PLC now owns 49,038 shares of the company’s stock valued at $51,000 after buying an additional 31,333 shares in the last quarter. 97.29% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have recently commented on VOR shares. JMP Securities restated a “market outperform” rating and issued a $12.00 price objective on shares of Vor Biopharma in a research report on Friday, September 6th. Barclays lowered their price target on Vor Biopharma from $10.00 to $3.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 14th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $17.50 price target on shares of Vor Biopharma in a research note on Friday, September 6th. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $10.92.

Vor Biopharma Stock Performance

NYSE VOR opened at $0.67 on Friday. The stock’s fifty day moving average is $0.88 and its two-hundred day moving average is $1.29. The firm has a market capitalization of $45.92 million, a P/E ratio of -0.38 and a beta of -0.35. Vor Biopharma Inc. has a fifty-two week low of $0.63 and a fifty-two week high of $3.14.

Vor Biopharma (NYSE:VOR) last released its quarterly earnings data on Thursday, August 8th. The company reported ($0.41) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.41). As a group, sell-side analysts forecast that Vor Biopharma Inc. will post -1.51 EPS for the current year.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.